LOSARTA 50

Țară: Israel

Limbă: engleză

Sursă: Ministry of Health

Cumpara asta acum

Prospect Prospect (PIL)
06-03-2023

Ingredient activ:

LOSARTAN POTASSIUM

Disponibil de la:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Codul ATC:

C09CA01

Forma farmaceutică:

TABLETS

Compoziție:

LOSARTAN POTASSIUM 50 MG

Calea de administrare:

PER OS

Tip de prescriptie medicala:

Required

Produs de:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Grupul Terapeutică:

LOSARTAN

Zonă Terapeutică:

LOSARTAN

Indicații terapeutice:

Hypertension: Losarta 50 mg is indicated for the treatment of hypertensionHeart failure: Losarta 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate.Switching patients with heart failure who are stable on an ACE inhibitor to Losarta 50 mg is not recommended.Renal protection in Type-2 diabetic patients with proteinuria: Losarta 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losarta 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.The benefit of Losarta 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Data de autorizare:

2023-11-30

Prospect

                                PATIENT LEAFLET IN ACCORDANCE WITH
THE PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s
prescription only
LOSARTA 50 TABLETS
EACH TABLET CONTAINS:
Losartan Potassium 50 mg
For a list of inactive ingredients – see section 6.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
MEDICINE. This leaflet contains concise information
about LOSARTA 50. If you have any other questions,
refer to the doctor or the pharmacist.
This medicine has been prescribed for your treatment.
Do not pass it on to others. It may harm them, even if
their medical condition seems similar to yours.
1. WHAT IS THE MEDICINE INTENDED FOR?
LOSARTA 50 is indicated for treatment of heart failure.
LOSARTA 50 is also indicated for treatment of
hypertension (high blood pressure) and to help lower
the risk for cardiovascular events, such as a stroke, in
patients with high blood pressure and a thickening of
the left ventricle (the heart’s main pumping chamber).
LOSARTA 50 also provides kidney protection by delaying
the worsening of kidney disease in type-2 diabetic
patients with protein in their urine (proteinuria).
Therapeutic class: the active ingredient belongs to the
angiotensin II receptor antagonists group.
2. BEFORE USING THE MEDICINE: DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient
losartan or to any of the other ingredients of this
medicine (see section 6).
•
You are more than 3 months pregnant (it is also
better to avoid LOSARTA 50 in early pregnancy)
(see the section “Pregnancy, breastfeeding and
fertility”).
•
You have a severe impairment in liver function.
•
You have diabetes or impaired kidney function
and you are treated with a blood pressure
lowering medicine containing aliskiren.
SPECIAL WARNINGS REGARDING THE USE OF THE
MEDICINE:
Talk to your doctor, pharmacist or nurse before taking
this medicine.
•
You must tell your doctor if you think you are
pregnant (or might become pregnant).
LOSARTA 50 is not recommended in early pregnancy,
and mu
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect arabă 06-03-2023
Prospect Prospect ebraică 06-03-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor